Company registration number 12668901 (England and Wales)
DISPHARMA UK LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 SEPTEMBER 2025
PAGES FOR FILING WITH REGISTRAR
DISPHARMA UK LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 8
DISPHARMA UK LIMITED
BALANCE SHEET
AS AT 30 SEPTEMBER 2025
30 September 2025
- 1 -
30 September 2025
31 March 2024
Notes
£
£
£
£
Fixed assets
Intangible assets
3
1,769,444
1,964,444
Tangible assets
4
41,639
42,779
1,811,083
2,007,223
Current assets
Stocks
164,431
164,431
Debtors
5
452,230
255,793
Cash at bank and in hand
212
165
616,873
420,389
Creditors: amounts falling due within one year
6
(3,199,755)
(1,060,631)
Net current liabilities
(2,582,882)
(640,242)
Total assets less current liabilities
(771,799)
1,366,981
Creditors: amounts falling due after more than one year
7
-
0
(1,824,208)
Net liabilities
(771,799)
(457,227)
Capital and reserves
Called up share capital
8
100
100
Profit and loss reserves
(771,899)
(457,327)
Total equity
(771,799)
(457,227)
DISPHARMA UK LIMITED
BALANCE SHEET (CONTINUED)
AS AT 30 SEPTEMBER 2025
30 September 2025
- 2 -

For the financial period ended 30 September 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the period in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 9 July 2026 and are signed on its behalf by:
Mr I Fazal
Director
Company registration number 12668901 (England and Wales)
DISPHARMA UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 SEPTEMBER 2025
- 3 -
1
Accounting policies
Company information

Dispharma UK Limited is a private company limited by shares incorporated in England and Wales. The registered office is 183 Alum Rock Road, Saltley, Birmingham, B8 1NJ.

1.1
Reporting period

The period has been extended to cover 18 months to bring the year end in line with the other companies in the group and therefore, comparative amounts presented in the financial statements (including the related notes) are not entirely comparable.

1.2
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.3
Going concern

A true t the time of approving the financial statements, t he directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus t he directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.4
Revenue

Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.

When cash inflows are deferred and represent a financing arrangement, the promised consideration is adjusted for the effects of the time value of money, which is recognised as interest income.

1.5
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is twenty years.

For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.

1.6
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

DISPHARMA UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 30 SEPTEMBER 2025
1
Accounting policies
(Continued)
- 4 -

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold land and buildings
5% Straight Line
Plant and equipment
25% Straight Line
Fixtures and fittings
25% Straight Line
Computers
25% Straight Line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.7
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

1.8
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.9
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.10
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

DISPHARMA UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 30 SEPTEMBER 2025
1
Accounting policies
(Continued)
- 5 -
Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future paymen ts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. A m ounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.11
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.12
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.13
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.14
Leases
As lessee

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease s asset are consumed.

DISPHARMA UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 30 SEPTEMBER 2025
- 6 -
2
Employees

The average monthly number of persons (including directors) employed by the company during the period was:

2025
2024
Number
Number
Total
29
33
3
Intangible fixed assets
Goodwill
£
Cost
At 1 April 2024 and 30 September 2025
2,600,000
Amortisation and impairment
At 1 April 2024
635,556
Amortisation charged for the period
195,000
At 30 September 2025
830,556
Carrying amount
At 30 September 2025
1,769,444
At 31 March 2024
1,964,444
4
Tangible fixed assets
Land and buildings
Plant and machinery etc
Total
£
£
£
Cost
At 1 April 2024
29,743
53,680
83,423
Additions
-
0
23,823
23,823
At 30 September 2025
29,743
77,503
107,246
Depreciation and impairment
At 1 April 2024
4,461
36,183
40,644
Depreciation charged in the period
2,231
22,732
24,963
At 30 September 2025
6,692
58,915
65,607
Carrying amount
At 30 September 2025
23,051
18,588
41,639
At 31 March 2024
25,282
17,497
42,779
DISPHARMA UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 30 SEPTEMBER 2025
- 7 -
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
362,239
209,812
Other debtors
89,991
45,981
452,230
255,793
6
Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans and overdrafts
186,405
151,665
Trade creditors
422,162
308,214
Amounts owed to group undertakings
2,154,258
144,776
Taxation and social security
14,488
20,077
Other creditors
422,442
435,899
3,199,755
1,060,631
7
Creditors: amounts falling due after more than one year
2025
2024
£
£
Bank loans and overdrafts
-
0
1,824,208
Creditors which fall due after five years are payable as follows:
Payable by instalments
-
1,348,328

The long term bank borrowing is secured over the assets of the company which is held by Lloyds Bank Plc.

8
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary Shares of £1 each
100
100
100
100
9
Related party transactions

The company has taken advantage of exemption under section 33.1A of FRS 102, from the requirement to disclose transactions with wholly owned members of the group.

10
Parent company
DISPHARMA UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 30 SEPTEMBER 2025
10
Parent company
(Continued)
- 8 -

The parent company of the company is Dispharma Retail Limited, a company which is incorporated in England and Wales.

The ultimate controlling party of the company is G F Corporation Limited, a company incorporated in England and Wales due to the shareholdings in the parent company.

2025-09-30 2024-04-01 false false false 09 July 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Mr I Fazal Mr N Fazal Mr S Fazal 12668901 2024-04-01 2025-09-30 12668901 2025-09-30 12668901 2024-03-31 12668901 core:NetGoodwill 2025-09-30 12668901 core:NetGoodwill 2024-03-31 12668901 core:LandBuildings 2025-09-30 12668901 core:OtherPropertyPlantEquipment 2025-09-30 12668901 core:LandBuildings 2024-03-31 12668901 core:OtherPropertyPlantEquipment 2024-03-31 12668901 core:CurrentFinancialInstruments core:WithinOneYear 2025-09-30 12668901 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 12668901 core:Non-currentFinancialInstruments core:AfterOneYear 2025-09-30 12668901 core:Non-currentFinancialInstruments core:AfterOneYear 2024-03-31 12668901 core:CurrentFinancialInstruments 2025-09-30 12668901 core:CurrentFinancialInstruments 2024-03-31 12668901 core:ShareCapital 2025-09-30 12668901 core:ShareCapital 2024-03-31 12668901 core:RetainedEarningsAccumulatedLosses 2025-09-30 12668901 core:RetainedEarningsAccumulatedLosses 2024-03-31 12668901 core:ShareCapitalOrdinaryShareClass1 2025-09-30 12668901 core:ShareCapitalOrdinaryShareClass1 2024-03-31 12668901 bus:Director1 2024-04-01 2025-09-30 12668901 core:Goodwill 2024-04-01 2025-09-30 12668901 core:LandBuildings core:LongLeaseholdAssets 2024-04-01 2025-09-30 12668901 core:PlantMachinery 2024-04-01 2025-09-30 12668901 core:FurnitureFittings 2024-04-01 2025-09-30 12668901 core:ComputerEquipment 2024-04-01 2025-09-30 12668901 2023-04-01 2024-03-31 12668901 core:NetGoodwill 2024-03-31 12668901 core:NetGoodwill 2024-04-01 2025-09-30 12668901 core:LandBuildings 2024-03-31 12668901 core:OtherPropertyPlantEquipment 2024-03-31 12668901 2024-03-31 12668901 core:LandBuildings 2024-04-01 2025-09-30 12668901 core:OtherPropertyPlantEquipment 2024-04-01 2025-09-30 12668901 core:Non-currentFinancialInstruments 2025-09-30 12668901 core:Non-currentFinancialInstruments 2024-03-31 12668901 bus:OrdinaryShareClass1 2024-04-01 2025-09-30 12668901 bus:OrdinaryShareClass1 2025-09-30 12668901 bus:OrdinaryShareClass1 2024-03-31 12668901 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-09-30 12668901 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-09-30 12668901 bus:FRS102 2024-04-01 2025-09-30 12668901 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-09-30 12668901 bus:Director2 2024-04-01 2025-09-30 12668901 bus:Director3 2024-04-01 2025-09-30 12668901 bus:FullAccounts 2024-04-01 2025-09-30 xbrli:pure xbrli:shares iso4217:GBP